Xeris Biopharma Holdings (XERS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- —
- Surprise
- -154.1%
- Revenue (period 2026-06-30)
- $92.1M
- Score at report (before → after)
- 6.4 → 6.4/10
Revenue source: xbrl.
How the report landed
TrendMatrix's engine moved from Hold (6.4/10) to Sell at 6.4/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates XERS Hold at 6.1/10.
0 of the last 4 quarters beat the estimate; this quarter's -154.1% surprise compares with a +338.5% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Concentration risk — Supplier: Regis Technologies
- Concentration risk — Supplier: Lonza Tampa
- Overbought (RSI 76)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.07
- Price target
- $11.19
- Stop
- $9.37
- Upside to target
- +11.1%
- Reward-to-risk
- 0.7:1
Risk check: RSI 76 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
XERS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.84B
- P/E (fwd)
- 27.2
- 52-week range
- $5.25–$11.33
- Off 52-week high
- 11.1%
- RSI (14)
- 76
- Volume vs avg
- 0.69×
- Score today
- 6.1/10